Cargando…
Testing For SARS‐CoV‐2: The Day the World Turned its Attention to the Clinical Laboratory
In the last few months, an unprecedented number of laboratory tests for coronavirus disease 2019 (COVID‐19) have been developed at a remarkable speed. With the rapid adoption of these tests into clinical practice, combined with the widespread publicity they received, questions arose related to the d...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7300945/ https://www.ncbi.nlm.nih.gov/pubmed/32475012 http://dx.doi.org/10.1111/cts.12828 |
_version_ | 1783547608147427328 |
---|---|
author | Zhao, Xuemei Markensohn, Julia F. Wollensak, David A. Laterza, Omar F. |
author_facet | Zhao, Xuemei Markensohn, Julia F. Wollensak, David A. Laterza, Omar F. |
author_sort | Zhao, Xuemei |
collection | PubMed |
description | In the last few months, an unprecedented number of laboratory tests for coronavirus disease 2019 (COVID‐19) have been developed at a remarkable speed. With the rapid adoption of these tests into clinical practice, combined with the widespread publicity they received, questions arose related to the different types of tests, their utility, performance, and regulatory approval status. The aim of this publication is to provide a general landscape of laboratory testing for COVID‐19 and offer a historical and regulatory perspective associated with them. Specifically, we aim to elaborate on the regulatory complexities of diagnostic testing in the United States and its implications to the present outbreak, as well as provide a synopsis of laboratory tests that have been developed for COVID‐19. We will first address the detection of severe acute respiratory syndrome‐coronavirus 2 directly by either nucleic acid amplification tests or by the detection of the viral protein for active infections. Subsequently, we will provide an overview of serological tests that can aid not only in diagnosis but additionally help to identify prior infections and potential immunity. |
format | Online Article Text |
id | pubmed-7300945 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-73009452020-06-18 Testing For SARS‐CoV‐2: The Day the World Turned its Attention to the Clinical Laboratory Zhao, Xuemei Markensohn, Julia F. Wollensak, David A. Laterza, Omar F. Clin Transl Sci Reviews In the last few months, an unprecedented number of laboratory tests for coronavirus disease 2019 (COVID‐19) have been developed at a remarkable speed. With the rapid adoption of these tests into clinical practice, combined with the widespread publicity they received, questions arose related to the different types of tests, their utility, performance, and regulatory approval status. The aim of this publication is to provide a general landscape of laboratory testing for COVID‐19 and offer a historical and regulatory perspective associated with them. Specifically, we aim to elaborate on the regulatory complexities of diagnostic testing in the United States and its implications to the present outbreak, as well as provide a synopsis of laboratory tests that have been developed for COVID‐19. We will first address the detection of severe acute respiratory syndrome‐coronavirus 2 directly by either nucleic acid amplification tests or by the detection of the viral protein for active infections. Subsequently, we will provide an overview of serological tests that can aid not only in diagnosis but additionally help to identify prior infections and potential immunity. John Wiley and Sons Inc. 2020-06-29 2020-09 /pmc/articles/PMC7300945/ /pubmed/32475012 http://dx.doi.org/10.1111/cts.12828 Text en © 2020 Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. Clinical and Translational Science published by Wiley Periodicals LLC on behalf of the American Society of Clinical Pharmacology & Therapeutics. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Reviews Zhao, Xuemei Markensohn, Julia F. Wollensak, David A. Laterza, Omar F. Testing For SARS‐CoV‐2: The Day the World Turned its Attention to the Clinical Laboratory |
title | Testing For SARS‐CoV‐2: The Day the World Turned its Attention to the Clinical Laboratory |
title_full | Testing For SARS‐CoV‐2: The Day the World Turned its Attention to the Clinical Laboratory |
title_fullStr | Testing For SARS‐CoV‐2: The Day the World Turned its Attention to the Clinical Laboratory |
title_full_unstemmed | Testing For SARS‐CoV‐2: The Day the World Turned its Attention to the Clinical Laboratory |
title_short | Testing For SARS‐CoV‐2: The Day the World Turned its Attention to the Clinical Laboratory |
title_sort | testing for sars‐cov‐2: the day the world turned its attention to the clinical laboratory |
topic | Reviews |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7300945/ https://www.ncbi.nlm.nih.gov/pubmed/32475012 http://dx.doi.org/10.1111/cts.12828 |
work_keys_str_mv | AT zhaoxuemei testingforsarscov2thedaytheworldturneditsattentiontotheclinicallaboratory AT markensohnjuliaf testingforsarscov2thedaytheworldturneditsattentiontotheclinicallaboratory AT wollensakdavida testingforsarscov2thedaytheworldturneditsattentiontotheclinicallaboratory AT laterzaomarf testingforsarscov2thedaytheworldturneditsattentiontotheclinicallaboratory |